Skip to main content
Clinical Trials/NCT03346486
NCT03346486
Completed
Not Applicable

Open, Fixed Sequence Diet-switch 4-week Intervention on the Effects of Brain-friendly Diet on Metabolic and Physiological Parameters and Cognitive Performance in Office Workers at Assumed Metabolic Risk

Fazer Group1 site in 1 country88 target enrollmentAugust 24, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Physiological Stress
Sponsor
Fazer Group
Enrollment
88
Locations
1
Primary Endpoint
Change in LDL cholesterol
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

To evaluate the effect of dietary intervention on metabolic risk profile, and on potential simultaneous changes in physiological and cognitive functions and to collect a unique database using state-of-the-art technologies on variables related to the above mentioned areas.

Detailed Description

The study is compiled from 4 phases: 1) a pilot study to evaluate performance and feasibility of the measurements and logistics for the BRAVE intervention study (N=10), 2) a pre-screening phase to select volunteers for the intervention study based on metabolite analyses (N=600), 3) the BRAVE intervention study as a controlled non-randomized open-label fixed sequence diet switch trial (N=88)and 4) a non-interventional reference group to estimate the learning effect due to repeated cognitive testing (N=30). The Brainfood dietary regime is planned optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work -according to the so-called plate model and optimized recipes- will be provided.

Registry
clinicaltrials.gov
Start Date
August 24, 2017
End Date
April 3, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Fazer Group
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in LDL cholesterol

Time Frame: 8 weeks

Change in serum LDL concentration between control period and intervention period

Secondary Outcomes

  • Change in serum metabolite concentrations(8 weeks)
  • Change in cognitive performance(4 weeks)
  • Changes in self-reported vigilance(4 weeks)
  • Changes in self-reported task load(4 weeks)
  • Daily pulse profile (evening- night- morning)(8 weeks)
  • Daily profile of heart rate variability (evening- night- morning)(8 weeks)
  • Number of adverse events(8 weeks)
  • Change in dietary habits and nutrient intake(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials